GlobeNewswire Inc | Nov 4, 2021 08:00AM EDT

November 04, 2021

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced presentations at three scientific conferences in November.

Event: Protein & Antibody Engineering Summit (PEGS) EuropePresenter: Lawrence Lamb, Ph.D., Executive Vice President, Chief Scientific Officer and co-founder of IN8bio A Pivotal Role for Concurrent Chemotherapy and ?? T Cell TherapyPresentation: (Drug Resistant Therapy ? DRI) in the Post-Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor MicroenvironmentDate: November 4Time: 9 a.m. CETLocation: Hotel Arts Ritz Carleton, Barcelona Event: Society for Immunotherapy of Cancer (SITC) 36th Annual MeetingPresenter: Kate Rochlin, Ph.D., Vice President, Operations and Innovation at IN8bio Poster 158: Chemotherapy Resistant Gamma Delta T-cellPresentation: Immunotherapy can leverage synergistic ligand expression through combinational chemotherapy and PARP-inhibitor use to enhance tumor cell recognition & killingDate: November 13thTime: 7 to 8:30 p.m. ESTLocation: Walter E. Washington Convention Center, Washington, D.C. Event: Society for Neuro-Oncology 26th Annual MeetingPresenter Lei Ding, Ph.D., Staff Scientist ? CAR T Lead, IN8bioPresentation: Poster: Dual chlorotoxin CAR and MGMT ?? T cells for drug resistant immunotherapy of glioblastoma multiformeDate: November 19Time: 7:30 to 9:30 p.m. ESTLocation: Hynes Convention Center, Boston Event: Society for Neuro-Oncology 26th Annual MeetingSponsor: IN8bio-sponsored academic researchPresenter: Anita Hjelmeland, Ph.D., and Amber JonesPresentation: Poster: Enhancing Glioblastoma Cell Stress Response to Improve Gamma Delta T-Cell ImmunotherapyDate: November 19Time: 7:30 to 9:30 p.m. ESTLocation: Hynes Convention Center, Boston

About IN8bioIN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bios DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.

For more information about IN8bio and its programs, please visitwww.IN8bio.com.

Company Contact:IN8bio, Inc.Kate Rochlin, Ph.D.+1 646.600.6GDT (6438)info@IN8bio.com

Investors:Solebury TroutDavid Buck+ 1 646.378.2927dbuck@soleburytrout.com

Media:Burns McClellan, Inc.Robert Flamm, Ph.D. / Harrison Wong+1 212.213.0006 - ext. 364 / 316rflamm@burnsmc.com/hwong@burnsmc.com